Pustular Psoriasis: Recognizing and Treating A Rare But Serious Disease

Format: Webcourse

Credit(s): 1.00 (60 min)

Release Date: Jun 21, 2021

Expiration Date: Jun 21, 2022

Credit Type(s):

CME / AMA PRA Category 1 Credit™
Physicians/ABIM MOC – ABIM MOC Point(s)

PROGRAM OVERVIEW

Pustular psoriasis is a clinically heterogenous group of rare psoriasis subtypes characterized by aseptic, neutrophil-rich pustules. The three most common types are generalized pustular psoriasis, palmoplantar pustular psoriasis, and acrodermatitis continua of Hallopeau. The diagnosis of pustular psoriasis relies mainly on clinical features and is challenging. Recent guidelines on diagnosis, classification, and assessment of severity have been published by ERASPEN and by the Japanese Dermatological Association.

Current systemic treatment has involved cyclosporine, methotrexate or acitretin. The Japanese Dermatological Association has also published guidelines that include a treatment algorithm. However, it has been recognized that IL-36 cytokines are likely the key driver of the autoimmune response in pustular psoriasis. There are two novel, investigational monoclonal antibodies that target the IL-36 receptor. In addition, agents that target other molecules have also been investigated.

Pustular Psoriasis: Recognizing and Treating A Rare But Serious Disease will review the most recent guidelines for diagnosing, classifying, and assessing the severity of pustular psoriasis and provide information on current treatment guidelines and agents in development to manage this rare group of disorders.